Notable Labs

Notable Labs Retained Earnings

The Retained Earnings of Notable Labs (NTBLQ) as of Nov 8, 2026 is -82.31 M USD. In the previous year, Retained Earnings was -294.38 M USD — a change of -72.04% (higher).

Retained Earnings

-82.31 MUSD

YoY

-72.04%

Last updated:

Retained Earnings of Notable Labs is 2023 -82.31 M USD. Retained Earnings of Notable Labs was 2022 -294.38 M USD. It decreases by -72.04% higher compared to the previous year.

The Notable Labs Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2016
-155.09 M USD
Jan 1, 2017
-165.23 M USD
Jan 1, 2018
-180.74 M USD
Jan 1, 2019
-200.02 M USD
Jan 1, 2020
-221.75 M USD
Jan 1, 2021
-258.95 M USD
Jan 1, 2022
-294.38 M USD
Jan 1, 2023
-82.31 M USD
The Notable Labs Retained Earnings history
YEARRetained EarningsYoY
-82.31 MUSD-72.04%
-294.38 MUSD+13.68%
-258.95 MUSD+16.78%
-221.75 MUSD+10.86%
-200.02 MUSD+10.67%
-180.74 MUSD+9.39%
-165.23 MUSD+6.54%
-155.09 MUSD+11.50%
-139.09 MUSD+9.38%
-127.16 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Retained Earnings of Notable Labs is -82.31 M USD in 2023.

Retained Earnings of Notable Labs changed from -294.38 M USD to -82.31 M USD, representing a -72.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Notable Labs

All Key Metrics — Notable Labs